{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:44:45Z","timestamp":1786985085658,"version":"build-2736575974"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100011841","name":"Xinxiang Medical University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011841","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.bcp.2025.117636","type":"journal-article","created":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T16:02:40Z","timestamp":1765641760000},"page":"117636","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Preparation and anti-tumor applications of universal umbilical cord blood-derived, mesothelin-targeted CAR-T cells"],"prefix":"10.1016","volume":"245","author":[{"given":"Zhitao","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guizeng","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yating","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongbing","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shihui","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moli","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.bcp.2025.117636_b0005","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s13045-025-01736-9","article-title":"Targeting triple-negative breast cancer using cord-blood CD34+ HSPC-derived mesothelin-specific CAR-NKT cells with potent antitumor activity","volume":"18","author":"Li","year":"2025","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.bcp.2025.117636_b0010","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/bs.apcsb.2024.10.008","article-title":"Revolutionizing pancreatic cancer treatment with CAR-T therapy","volume":"144","author":"Baghel","year":"2025","journal-title":"Adv. Protein Chem. Struct. Biol."},{"key":"10.1016\/j.bcp.2025.117636_b0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2025.104785","article-title":"A new approach to the treatment of ovarian cancer: the application of CAR-T cell therapy","volume":"213","author":"Yang","year":"2025","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"5","key":"10.1016\/j.bcp.2025.117636_b0020","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.3390\/biomedicines13051215","article-title":"Targeting Aggressive Prostate Carcinoma Cells with Mesothelin-CAR-T Cells","volume":"13","author":"de Testas de Folmont","year":"2025","journal-title":"Biomedicines"},{"key":"10.1016\/j.bcp.2025.117636_b0025","doi-asserted-by":"crossref","unstructured":"Ji F, Yu J, Zhu Y, et al.B4M3 CAR-T cell enhance antitumor activity and non-tumor toxicity in ovarian cancer. Int Immunopharmacol. 2025,159:114919.","DOI":"10.1016\/j.intimp.2025.114919"},{"issue":"7","key":"10.1016\/j.bcp.2025.117636_b0030","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1007\/s00262-025-04039-7","article-title":"Enhancing mesothelin CAR T cell therapy for pancreatic cancer with an oncolytic herpes virus boosting CAR target antigen expression","volume":"74","author":"Aboalela","year":"2025","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.bcp.2025.117636_b0035","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1389971","article-title":"The synergistic immunotherapeutic impact of engineered CAR-T cells with PD-1 blockade in lymphomas and solid tumors: a systematic review","volume":"15","author":"Satapathy","year":"2024","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.bcp.2025.117636_b0040","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010966","article-title":"PDZ domains of PATJ facilitate immunological synapse formation to promote T cell activation","volume":"13","author":"Xiong","year":"2025","journal-title":"J. Immunother. Cancer"},{"issue":"5","key":"10.1016\/j.bcp.2025.117636_b0045","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009825","article-title":"Development and optimization of Eva1 MPZL2 targeting chimeric antigen receptor T cells","volume":"13","author":"Osaki","year":"2025","journal-title":"J. Immunother. Cancer"},{"issue":"7","key":"10.1016\/j.bcp.2025.117636_b0050","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.3390\/cancers17071118","article-title":"Mesothelin as a Signal Pathways and Epigenetic Target in Cancer Therapy","volume":"17","author":"Kumari","year":"2025","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bcp.2025.117636_b0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2025.155947","article-title":"CAR T cells in lung cancer: Targeting tumor-associated antigens to revolutionize immunotherapy","volume":"269","author":"Alenezi","year":"2025","journal-title":"Pathol. Res. Pract."},{"key":"10.1016\/j.bcp.2025.117636_b0060","doi-asserted-by":"crossref","unstructured":"Yin X, Chen W, Ao X, et al. Sodium citrate pretreatment enhances CAR-T cell persistence and anti-tumor efficacy through inhibition of calcium signaling.Front Immunol. 2025,16:1540754.","DOI":"10.3389\/fimmu.2025.1540754"},{"issue":"8","key":"10.1016\/j.bcp.2025.117636_b0065","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1038\/s41423-025-01314-6","article-title":"CD2 augmentation enhances CAR-T-cell efficacy via immunological synapse remodeling and T-cell exhaustion mitigation","volume":"22","author":"Zhu","year":"2025","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.bcp.2025.117636_b0070","doi-asserted-by":"crossref","unstructured":"Wang Y, Tong C, Dai H, et al. Low-dose decitabine priming endows CAR T cells with enhanced and persistent antitumour potential via epigenetic reprogramming. Nat Commun. 2021,12(1):409.","DOI":"10.1038\/s41467-020-20696-x"},{"issue":"11","key":"10.1016\/j.bcp.2025.117636_b0075","first-page":"779","article-title":"Reciprocal activation of antigen-presenting cells and CAR T cells triggers a widespread endogenous anti-tumor immune response through sustained high-level IFN\u03b3 production","volume":"20","author":"Guo","year":"2023","journal-title":"Cancer Biol. Med."},{"issue":"1","key":"10.1016\/j.bcp.2025.117636_b0080","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/s41392-023-01659-2","article-title":"Characteristics of premanufacture CD8+T cells determine CAR-T efficacy in patients with diffuse large B-cell lymphoma","volume":"8","author":"Wang","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"issue":"8","key":"10.1016\/j.bcp.2025.117636_b0085","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.jgg.2019.06.007","article-title":"Blocking CD38-driven fratricide among T cells enables effective antitumor activity by CD38-specific chimeric antigen receptor T cells","volume":"46","author":"Gao","year":"2019","journal-title":"J. Genet. Genomics"},{"key":"10.1016\/j.bcp.2025.117636_b0090","unstructured":"Gao ZT. (2021). Composition of stem cell extract and antimicrobial peptide and its use (CN201810244340.7) [Granted Patent]. China: State Intellectual Property Office of the People's Republic of China."},{"issue":"6","key":"10.1016\/j.bcp.2025.117636_b0095","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.3390\/medicina61061042","article-title":"Protective effect of Mesenchymal Stem Cell-Derived Extracellular Vesicles on inner Ear Sensorineural Cells Affected by Cisplatin","volume":"61","author":"Perde-Schrepler","year":"2025","journal-title":"Medicina (Kaunas)"},{"key":"10.1016\/j.bcp.2025.117636_b0100","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1485461","article-title":"Anti-Mesothelin CAR-NK cells as a novel targeted therapy against cervical cancer","volume":"15","author":"Kutle","year":"2024","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.bcp.2025.117636_b0105","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s00262-024-03909-w","article-title":"CCR5 and IL-12 co-expression in CAR T cells improves antitumor efficacy by reprogramming tumor microenvironment in solid tumors","volume":"74","author":"Tian","year":"2025","journal-title":"Cancer Immunol. Immunother."},{"issue":"2","key":"10.1016\/j.bcp.2025.117636_b0110","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/leu.2014.215","article-title":"IL-12-secreting CD19-targeted cord blood-derived T cells for the immunotherapy of B-cell acute lymphoblastic leukemia","volume":"29","author":"Pegram","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.bcp.2025.117636_b0115","doi-asserted-by":"crossref","unstructured":"Misawa K, Bhat H, Adusumilli PS, et al. Combinational CAR T-cell therapy for solid tumors: Requisites, rationales, and trials. Pharmacol. Ther. 202,266:108763.","DOI":"10.1016\/j.pharmthera.2024.108763"},{"issue":"22","key":"10.1016\/j.bcp.2025.117636_b0120","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.186268","article-title":"Affinity-tuned mesothelin CAR T cells demonstrate enhanced targeting specificity and reduced off-tumor toxicity","volume":"9","author":"Yang","year":"2024","journal-title":"JCI Insight"},{"issue":"11","key":"10.1016\/j.bcp.2025.117636_b0125","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.70057","article-title":"Persistence of activated anti-mesothelin hYP218 chimeric antigen receptor T cells in the tumour is associated with efficacy in gastric and colorectal carcinomas","volume":"14","author":"Mir","year":"2024","journal-title":"Clin. Transl. Med."},{"issue":"1","key":"10.1016\/j.bcp.2025.117636_b0130","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s13073-024-01405-5","article-title":"Efficacy and safety of novel multiple-chain DAP-CAR-T cells targeting mesothelin in ovarian cancer and mesothelioma: a single-arm, open-label and first-in-human study","volume":"16","author":"Xu","year":"2024","journal-title":"Genome Med."},{"key":"10.1016\/j.bcp.2025.117636_b0135","doi-asserted-by":"crossref","unstructured":"Galvagno F, Leuci V, Massa A, et al.Three-dimensional dynamics of mesothelin-targeted CAR.CIK lymphocytes against ovarian cancer peritoneal carcinomatosis. Cancer Immunol. Immunother. 2024,74(1):6.","DOI":"10.1007\/s00262-024-03860-w"},{"issue":"1","key":"10.1016\/j.bcp.2025.117636_b0140","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1007\/s12672-024-01455-6","article-title":"Design and development of dual targeting CAR protein for the development of CAR T-cell therapy against KRAS mutated pancreatic ductal adenocarcinoma using computational approaches","volume":"15","author":"Ramalingam","year":"2024","journal-title":"Discov. Oncol."},{"issue":"10","key":"10.1016\/j.bcp.2025.117636_b0145","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009510","article-title":"Microenvironmental alkalization promotes the therapeutic effects of MSLN-CAR-T cells","volume":"12","author":"Wu","year":"2024","journal-title":"J. Immunother. Cancer"},{"issue":"16","key":"10.1016\/j.bcp.2025.117636_b0150","doi-asserted-by":"crossref","first-page":"6249","DOI":"10.7150\/thno.97590","article-title":"Development of a CD39 nanobody and its enhancement to chimeric antigen receptor T cells efficacy against ovarian cancer in preclinical studies","volume":"14","author":"Zhang","year":"2024","journal-title":"Theranostics"}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295225009013?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295225009013?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T12:10:55Z","timestamp":1781698255000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295225009013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":30,"alternative-id":["S0006295225009013"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2025.117636","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preparation and anti-tumor applications of universal umbilical cord blood-derived, mesothelin-targeted CAR-T cells","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2025.117636","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117636"}}